|Defined daily dose||400 mg|
|Bioavailability||93% ± 9%|
|Elimination half-life||45 hours|
|Excretion||Kidney: <6% (parent drug)|
Biliary <5% (parent drug)
|Chemical and physical data|
|Molar mass||266.304 g·mol−1|
|3D model (JSmol)|
Nevirapine (NVP), marketed under the trade name Viramune among others, is a medication used to treat and prevent HIV/AIDS, specifically HIV-1. It is generally recommended for use with other antiretroviral medication. It may be used to prevent mother to child spread during birth but is not recommended following other exposures. It is taken by mouth.
Common side effects include rash, headache, nausea, feeling tired, and liver problems. The liver problems and skin rash may be severe and should be checked for during the first few months of treatment. It appears to be safe for use during pregnancy. It is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and works by blocking the function of reverse transcriptase.
Nevirapine was approved for medical use in the United States in 1996. It is on the World Health Organization's List of Essential Medicines, the safest and most effective medicines needed in a health system. It is available as a generic medication. The wholesale cost in the developing world is US$2.16 to $16.62 per month as of 2014. As of 2015, the cost for a typical month of medication in the United States was more than $200.
Nevirapine is used in adults and in children 6 years of age infected with HIV-1 as part of combination antiretroviral treatment (ART or cART). Monotherapy with nevirapine is not indicated due to rapid emergence of resistance.
Nevirapine in triple combination therapy has been shown to suppress viral load effectively when used as initial antiretroviral therapy (i.e., in antiretroviral-naive patients). Some clinical trials have demonstrated comparable HIV suppression with nevirapine-based regimens to that achieved with regimens based on a protease inhibitor (PI) or efavirenz.
This drug is generally only to be considered for use if the CD4 cell count is very low.
Although concerns have been raised about nevirapine-based regimens in those starting therapy with high viral load or low CD4 count, some analyses suggest that nevirapine may be effective in this group of people.
Nevirapine may also form a useful component of salvage regimens after virological failure, usually in combination with one or more PIs as well as nucleotide reverse transcriptase inhibitor (NRTIs), especially in those who have not previously taken an NNRTI.
Preventing mother-to-child transmission
A single dose of nevirapine given to both mother and child reduced the rate of HIV transmission by almost 50% compared with a very short course of zidovudine (AZT) prophylaxis, in a clinical trial in Uganda. A subsequent study in Thailand showed that prophylaxis with single-dose nevirapine in addition to zidovudine is more effective than zidovudine alone. These and other trials have led the World Health Organization to endorse the use of single-dose nevirapine prophylaxis in many developing world settings as a cost-effective way of reducing mother-to-child transmission. However, in the United States the Ugandan study was deemed flawed  and as of 2006 the FDA has not approved of such nevirapine prophylaxis. However, supporters of HIVNET 012 experiment argued that the flaws in this experiment were largely due to bureaucratic incompetence, while the findings regarding the safety and efficacy of single-dose nevirapine from this study were scientifically solid and too important to discard. Moreover, it was argued that holding African researchers who operated under resource-poor situations to the same moral and procedural standards to their Western counterparts was unrealistic, and would further marginalize African researchers' role in the science community and impede the progress of African science. Another clinical trial, Using Nevirapine to Prevent Mother-to-Child HIV Transmission During Breastfeeding, was completed in September 2013.
A major concern with this approach is that NNRTI resistance mutations are commonly observed in both mothers and infants after single-dose nevirapine, and may compromise the response to future NNRTI-containing regimens. A short course of maternal zidovudine/lamivudine is recommended by the U.S. Public Health Service Task Force to reduce this risk.
The defined daily dose is 400 mg by mouth. In those who weight more than 40 kg this is taken as 200 mg once per day for two weeks and than 200 mg twice per day. In children over 8 years old the dose is 4 mg/kg once per day for the first two weeks and than twice per day after that, while in those under 8 years old the dose is 4 mg/kg once per day for the first two weeks and than 7 mg/kg twice per day.
The most common adverse effect of nevirapine is the development of mild or moderate rash (13%). Severe or life-threatening skin reactions have been observed in 1.5% of patients, including Stevens–Johnson syndrome, toxic epidermal necrolysis and hypersensitivity.
Nevirapine may cause severe or life-threatening liver toxicity, usually emerging in the first six weeks of treatment. In 2000, the U.S. Food and Drug Administration issued a black box warning on nevirapine, warning that it could cause life-threatening liver toxicity and skin reactions. Unacceptably high risk of serious liver symptoms in certain patient groups (women with CD4 count >250 and men >400) has led the U.S. DHHS to recommend the restriction of nevirapine use to those at lower risk, unless the benefit to the patient clearly outweighs the risk; although in the 2NN study which found these CD4 limits, the effect was seen only in patients recruited from Thailand. More recent studies on the use of Nevirapine in people with higher CD4 cell counts have come to the following conclusion: Treatment-experienced patients who start NVP-based combination therapy with low pre–ART and high current CD4 cell counts and an undetectable VL have a similar likelihood for discontinuing NVP therapy because of hypersensitivity reactions (HSRs), compared with treatment-naive patients with low CD4 cell counts. This suggests that NVP-based combination therapy may be safely initiated in such patients. However, in similar patients with a detectable VL, it is prudent to continue to adhere to current CD4 cell count thresholds. The U.S. Public Health Service Task Force advocates caution in the use of nevirapine in pregnancy due to toxicity issues, which may be exacerbated during pregnancy.
The U.S. Food and Drug Administration recommends stopping nevirapine if a person experiences:
- sign and symptoms of liver issues such as hepatitis
- increased transaminases in addition to rash or systemic symptoms
- formation of rash with systemic symptoms
- severe skin or hypersensitivity reactions
Additionally, the U.S. FDA recommends close monitoring during the first 6 weeks of therapy for the above symptoms as there is high risk during this time. Continued monitoring is recommended for up to the first 18 weeks of treatment. If a patient experiences hepatitis plus rash or other systemic symptoms, or severe hypersensitivity or skin rash, nevirapine should not be restarted.
Nevirapine is a substrate for liver CYP3A and CYP2B6 enzymes. Concomitant administration of drugs that are inhibitors of these enzymes may increase serum nevirapine levels significantly. Some examples of these drugs include ritonavir, fosamprenavir, and fluconazole. On the other hand, drugs that are inducers of these enzymes such as rifampicin may lower serum nevirapine levels.
In addition, concomitant use of St. John's wort (Hypericum perforatum, which has been shown to induce CYP3A4 and CYP1A2) or St. John's wort containing products may significantly lower nevirapine levels.
Nevirapine is an inducer of cytochrome P450 isoenzymes CYP3A4 and CYP2B6. It may reduce levels of several co-administered drugs including the antiretrovirals efavirenz, indinavir, lopinavir, nelfinavir and saquinavir, as well as clarithromycin, ketoconazole, forms of hormonal contraception, and methadone.
Mechanism of action
Nevirapine falls in the non-nucleoside reverse transcriptase inhibitor (NNRTI) class of antiretrovirals. Both nucleoside and non-nucleoside RTIs inhibit the same target, the reverse transcriptase enzyme, an essential viral enzyme which transcribes viral RNA into DNA. Unlike nucleoside RTIs, which bind at the polymerase active site, NNRTIs bind to a hydrophobic pocket in the subdomain of p66 which is about 10 angstrom away from the active site (known as the NNRTI pocket). Therefore, this NNRTI-binding pocket will inhibit reverse transcription in a way that is distinct to the NRTIs.
Nevirapine is not effective against HIV-2, as the pocket of the HIV-2 reverse transcriptase has a different structure, which confers intrinsic resistance to the NNRTI class.
Resistance to nevirapine develops rapidly if viral replication is not completely suppressed. The most common mutations observed after nevirapine treatment are Y181C and K103N, which are also observed with other NNRTIs. As all NNRTIs bind within the same pocket, viral strains which are resistant to nevirapine are usually also resistant to the other NNRTIs, efavirenz and delavirdine. However, second generation NNRTIs like rilpivirine and etravirine are effective in treatment for HIV strains resistant to nevirapine and other first generation drugs in that same class.
Nevirapine was discovered by Karl D. Hargrave and colleagues at Boehringer Ingelheim Pharmaceuticals, Inc., one of the Boehringer Ingelheim group of companies. It is covered by U.S. Patent 5,366,972 and corresponding foreign patents. Nevirapine was the first NNRTI approved by the U.S. Food and Drug Administration (FDA). It was approved June 21, 1996 for adults and September 11, 1998 for children. It was also approved in Europe in 1997.
Society and culture
- https://medicalguidelines.msf.org/viewport/EssDr/english/nevirapine-nvp-oral-16684308.html. Retrieved 1 September 2020. Missing or empty
- "WHOCC - ATC/DDD Index". www.whocc.no. Retrieved 1 September 2020.
- "Nevirapine". The American Society of Health-System Pharmacists. Archived from the original on 20 December 2016. Retrieved 3 December 2016.
- Hamilton, Richart (2015). Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition. Jones & Bartlett Learning. p. 63. ISBN 9781284057560.
- World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- "Nevirapine". International Drug Price Indicator Guide. Retrieved 3 December 2016.
- "Product Information: VIRAMUNE(R)XR oral extended-release tablets, nevirapine oral extended-release tablets" (PDF). Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, 2011. 2011. Archived (PDF) from the original on 2016-11-06. Retrieved 2016-11-05.
- Montaner JS, Reiss P, Cooper D (Mar 1998). "A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study". JAMA. 279 (12): 930–7. doi:10.1001/jama.279.12.930. PMID 9544767.
- van Leeuwen R, Katlama C, Murphy RL (May 2003). "A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients". AIDS. 17 (7): 987–99. doi:10.1097/00002030-200305020-00007. PMID 12700448.
- Podzamczer D, Ferrer E, Consiglio E (2002). "A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study)". Antiviral Therapy. 7 (2): 81–90. PMID 12212928.
- van Leth F, Andrews S, Grinsztejn B (Mar 2005). "The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART". AIDS. 19 (5): 463–71. doi:10.1097/01.aids.0000162334.12815.5b. PMID 15764851.
- "Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children: Guidelines for the use of antiretroviral agents in pediatric HIV infection". AIDSinfo, U.S. Department of Health and Human Services (HHS). March 2016. Archived from the original on 2016-11-07. Retrieved 2016-11-05.
- Guay LA, Musoke P, Fleming T (Sep 1999). "Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial". Lancet. 354 (9181): 795–802. doi:10.1016/S0140-6736(99)80008-7. PMID 10485720.
- Lallemant M, Gonzague Jourdain G, Sophie Le Coeur S, et al. (2004) Single-Dose Perinatal Nevirapine plus Standard Zidovudine to Prevent Mother-to-Child Transmission of HIV-1 in Thailand. N Engl J Med 351: 217-28 Archived 2006-06-18 at the Wayback Machine
- The HIVNET 012 Study and the Safety and Effectiveness of Nevirapine in Preventing Mother-to-Infant Transmission of HIV, "Archived copy". Archived from the original on 2009-02-01. Retrieved 2009-01-23.CS1 maint: archived copy as title (link)
- Celia Farber, "Out of Control: AIDS and the Corruption of Science" "Archived copy". Archived from the original on 2009-05-04. Retrieved 2009-06-11.CS1 maint: archived copy as title (link)
- Crane, J 2010, 'Adverse events and placebo effects: African scientists, HIV, and ethics in the 'global health sciences, Social Studies Of Science, 40, 6, pp. 843-870 http://sss.sagepub.com.ezp.lib.unimelb.edu.au/content/40/6/843.full.pdf+html
- Lock, M. & Nguyen, V 2010, an Anthropology of Biomedicine, Malden, Wiley-Blackwell.
- "Archived copy". Archived from the original on 2008-12-05. Retrieved 2009-01-23.CS1 maint: archived copy as title (link)
- Johnson JA, Li JF, Morris L (Jul 2005). "Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated". J Infect Dis. 192 (1): 16–23. doi:10.1086/430741. PMID 15942889.
- Jourdain G, Ngo-Giang-Huong N, Le Coeur S (Jul 2004). "Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy". N Engl J Med. 351 (3): 229–40. doi:10.1056/NEJMoa041305. PMID 15247339.
- Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. "Archived copy" (PDF). Archived (PDF) from the original on 2014-04-12. Retrieved 2014-04-11.CS1 maint: archived copy as title (link). Accessed 16 November 2016.
- Viramune (nevirapine) tablets; Viramune (nevirapine) oral suspension prescribing information Archived 2006-11-12 at the Wayback Machine
- "Facts sheet from the AIDS Treatment Data Network". Archived from the original on 2006-01-13. Retrieved 2006-01-16.
- DHHS panel. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents (May 4, 2006). (Available for download from AIDSInfo Archived 2006-05-06 at the Wayback Machine)
- Viramune XR (nevirapine) FDA Prescribing Information Archived 2016-11-08 at the Wayback Machine
- Stern JO, Robinson PA, Love J, Lanes S, Imperiale MS, Mayers DL (2003). "A comprehensive hepatic safety analysis of nevirapine in different populations of HIV-infected patients". J Acquir Immune Defic Syndr. 34 (Suppl 1): S21–S33. doi:10.1097/00126334-200309011-00005. PMID 14562855.
- Wit FW, Kesselring AM, Gras L (Mar 2008). "Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment-naive patients: the ATHENA cohort study". Clin Infect Dis. 46 (6): 933–40. doi:10.1086/528861. PMID 18271750.
- "VIRAMUNE® (nevirapine) Prescribing Information" (PDF). Archived (PDF) from the original on 2016-11-08.
- Wenk M, Todesco L, Krähenbühl S (2004). "Effect of St John's wort on the activities of CYP1A2, CYP3A4, CYP2D6, N-acetyltransferase 2, and xanthine oxidase in healthy males and females". Br J Clin Pharmacol. 57 (4): 495–499. doi:10.1111/j.1365-2125.2003.02049.x. PMC 1884478. PMID 15025748.
- Patel SS, Benfield P (Oct 1996). "New drug profile: nevirapine". Clinical Immunotherapeutics. 6 (4): 307–317. doi:10.1007/BF03259093.
- Schauer, Grant D.; Huber, Kelly D.; Leuba, Sanford H.; Sluis-Cremer, Nicolas (2014-10-13). "Mechanism of allosteric inhibition of HIV-1 reverse transcriptase revealed by single-molecule and ensemble fluorescence". Nucleic Acids Research. 42 (18): 11687–11696. doi:10.1093/nar/gku819. ISSN 0305-1048. PMC 4191400. PMID 25232099.
- Ren J, Bird LE, Chamberlain PP, Stewart-Jones GB, Stuart DI, Stammers DK (Oct 2002). "Structure of HIV-2 reverse transcriptase at 2.35-A resolution and the mechanism of resistance to non-nucleoside inhibitors". Proc Natl Acad Sci USA. 99 (22): 14410–5. doi:10.1073/pnas.222366699. PMC 137897. PMID 12386343.
- Conway B, Wainberg MA, Hall D (Jul 2001). "Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine". AIDS. 15 (10): 1269–74. doi:10.1097/00002030-200107060-00008. PMID 11426071.